Tasly Pharmaceutical Group Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Tasly Pharmaceutical Group heeft een totaal eigen vermogen van CN¥13.0B en een totale schuld van CN¥2.1B, wat de schuld-eigenvermogensverhouding op 16.2% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥16.8B en CN¥3.8B. De EBIT Tasly Pharmaceutical Group is CN¥1.4B waardoor de rentedekking -44.7 is. Het heeft contanten en kortetermijnbeleggingen van CN¥5.0B.

Belangrijke informatie

16.2%

Verhouding schuld/eigen vermogen

CN¥2.11b

Schuld

Rente dekkingsratio	-44.7x
Contant	CN¥4.97b
Aandelen	CN¥13.02b
Totaal verplichtingen	CN¥3.82b
Totaal activa	CN¥16.83b

Recente financiële gezondheidsupdates

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Nov 17

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥9.1B ) 600535 } overtreffen de korte termijn passiva ( CN¥3.4B ).

Langlopende schulden: De kortetermijnactiva 600535 ( CN¥9.1B ) overtreffen de langetermijnschulden ( CN¥456.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 600535 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 600535 is de afgelopen 5 jaar gedaald van 71% naar 16.2%.

Schuldendekking: De schuld van 600535 wordt goed gedekt door de operationele kasstroom ( 126.6% ).

Rentedekking: 600535 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Tasly Pharmaceutical Group Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Upcoming dividend of CN¥0.26 per share

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% overvalued

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Price target increased by 8.7% to CN¥16.17

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Now 20% overvalued

Dividend of CN¥0.33 announced

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Earnings beat expectations, revenue disappoints

New 90-day high - CN¥19.62

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.